Analysts Offer Insights on Healthcare Companies: Global Blood Therapeutics (NASDAQ: GBT), Recro Pharma (NASDAQ: REPH) and Vascular Biogenics (NASDAQ: VBLT)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Global Blood Therapeutics (NASDAQ: GBT), Recro Pharma (NASDAQ: REPH) and Vascular Biogenics (NASDAQ: VBLT) with bullish sentiments.

Global Blood Therapeutics (NASDAQ: GBT)

In a report released yesterday, Mark Breidenbach from Roth Capital reiterated a Buy rating on Global Blood Therapeutics (NASDAQ: GBT), with a price target of $47. The company’s shares opened today at $18.15, close to its 52-week low of $12.24.

According to TipRanks.com, Breidenbach is ranked 0 out of 5 stars with an average return of -20.1% and a 23.4% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as RXi Pharmaceuticals Corp, Mateon Therapeutics Inc, and Cascadian Therapeutics.

Global Blood Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $83.

Recro Pharma (NASDAQ: REPH)

In a report released yesterday, Scott Henry from Roth Capital reiterated a Buy rating on Recro Pharma (NASDAQ: REPH), with a price target of $24. The company’s shares opened today at $9.48.

Henry wrote:

“We reiterate our Buy rating as we believe that IV meloxicam is approvable and could represent an alternative to opioid pain medications. REPH reports second positive efficacy trial for IV meloxicam. Recro Pharma announced positive results from its second phase 3 clinical trial evaluating intravenous (IV) meloxicam for the treatment of acute post operative pain following abdominoplasty surgery . IV meloxicam achieved its primary endpoint of a statistically significant difference in Summed Pain Intensity Difference (SPID) over the first 24 hours (p=0.0145). Data analysis. The study also achieved statistical significance for 10 of the 19 secondary endpoints with pain relief as early as SPID12 (SPID6 did work in the first trial, SPID48 achieved significance in both trials). Even the missed secondary endpoints appeared to trend in the right direction. Takeaway #1 – Road to market becoming clear. This was the second pivotal efficacy trial and the last remaining high risk event for investors, in our opinion. The gating factor to filing a New Drug Application (NDA), however, remains the long-term safety study (which should complete enrollment in late 1Q17/early 2Q17). We do not expect surprises in the long-term safety study given that the adverse event profile appears safe in the efficacy trials. Takeaway #2 – Filing target remains “summer 2017″.”

According to TipRanks.com, Henry is a 1-star analyst with an average return of -2.1% and a 37.9% success rate. Henry covers the Healthcare sector, focusing on stocks such as Acerus Pharmaceuticals Corporation, Flamel Technologies S.A., and Apricus Biosciences Inc.

Currently, the analyst consensus on Recro Pharma is Strong Buy and the average price target is $19, representing a 100.4% upside.

In a report issued on November 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $19 price target.
Vascular Biogenics (NASDAQ: VBLT)

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Vascular Biogenics (NASDAQ: VBLT), with a price target of $20. The company’s shares opened today at $5.80.

According to TipRanks.com, Amusa is ranked 0 out of 5 stars with an average return of -8.9% and a 37.2% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Dimension Therapeutics Inc, and Lion Biotechnologies Inc.

Vascular Biogenics has an analyst consensus of Strong Buy.